Viganor Livia, Howe Orla, McCarron Pauraic, McCann Malachy, Devereux Michael
The Centre for Biomimetic and Therapeutic Research, Focas Research Institute, Dublin Institute of Technology, Camden Row, Dublin 8, Ireland.
Chemistry Department, Maynooth University, National University of Ireland, Maynooth, Co. Kildare, Ireland.
Curr Top Med Chem. 2017;17(11):1280-1302. doi: 10.2174/1568026616666161003143333.
The "antibiotic era", characterized by the overuse and misuse of antibiotics, over the last half-century has culminated in the present critical "era of resistance". The treatment of bacterial infections is challenging because of a decline in the current arsenal of useful antibiotics and the slow rate of new drug development. The discovery of a new gene (mcr-1) in 2015, which enables bacteria to be highly resistant to polymyxins (such as colistin), the last line of antibiotic defence left, heralds a new level of concern as this gene is susceptible to horizontal gene transfer, with alarming potential to be spread between different bacterial populations, suggesting that the progression from "extensive drug resistance" to "pan-drug resistance" may be inevitable. Clearly there is a need for the development of novel classes of anti-bacterial agents capable of killing bacteria through mechanisms that are different to those of the known classes of antibiotics. 1,10-phenanthroline (phen) is a heterocyclic organic compound which exerts in vitro antimicrobial activity against a broad-spectrum of bacteria. The antimicrobial activity of phen can be significantly modulated by modifying its structure. The development of metal-phen complexes offers the medicinal chemist an opportunity to expand such structural diversity by controlling the geometry and varying the oxidation states of the metal centre, with the inclusion of appropriate auxiliary ligands in the structure, offering the opportunity to target different biochemical pathways in bacteria. In this review, we summarize what is currently known about the antibacterial capability of metal-phen complexes and their mechanisms of action.
在过去的半个世纪里,以抗生素的过度使用和滥用为特征的“抗生素时代”,最终演变成了当前严峻的“耐药时代”。由于现有有效抗生素库的减少以及新药研发速度缓慢,细菌感染的治疗面临着挑战。2015年发现的一种新基因(mcr - 1),使细菌对多粘菌素(如黏菌素)具有高度耐药性,而多粘菌素是仅存的最后一道抗生素防线,这引发了新的高度关注,因为该基因易于发生水平基因转移,具有在不同细菌群体之间传播的惊人潜力,这表明从“广泛耐药”发展到“全耐药”可能是不可避免的。显然,需要开发新型抗菌剂,其能够通过与已知抗生素类别不同的机制杀死细菌。1,10 - 菲咯啉(phen)是一种杂环有机化合物,对多种细菌具有体外抗菌活性。通过修饰其结构,可以显著调节phen的抗菌活性。金属 - phen配合物的开发为药物化学家提供了一个机会,通过控制金属中心的几何形状和改变其氧化态来扩展这种结构多样性,并在结构中引入适当的辅助配体,从而有机会靶向细菌中的不同生化途径。在这篇综述中,我们总结了目前关于金属 - phen配合物的抗菌能力及其作用机制的已知信息。